Axsome Therapeutics

Yahoo Finance • 23 days ago

3 Overlooked Stocks Set to Soar in 2026

Smaller biotech stocks often fly under the radar. Many of them aren't consistently profitable, but some can deliver outsize growth for investors. Axsome Therapeutics(NASDAQ: AXSM) is a mid-cap with only three approved therapies, while sma... Full story

Yahoo Finance • 24 days ago

Stocks making the biggest moves midday: Berkshire, AMD, Circle, FedEx, UPS & more

Check out the companies making the biggest moves in midday trading. Logistics firms — Shares of logistics companies were under pressure after Amazon said it would launch Amazon Supply Chain Services , its own freight, distribution, fulfill... Full story

Yahoo Finance • 24 days ago

Axsome (AXSM) Q2 2025 Earnings Transcript

Image source: The Motley Fool. DATE Monday, Aug. 4, 2025 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Herriot Tabuteau Chief Financial Officer — Nick Pizzie Chief Commercial Officer — Ari Maizel Chief Operating Officer — Ma... Full story

Yahoo Finance • 24 days ago

Axsome (AXSM) Q1 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Monday, May 5, 2025 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Dr. Herriot Tabuteau Chief Financial Officer — Nick Pizzie Chief Commercial Officer — Ari Maizel Chief Operating Office... Full story

Yahoo Finance • 24 days ago

Stocks making the biggest moves premarket: eBay, Norwegian Cruise Line, Coinbase & more

Check out the companies making the biggest moves premarket: eBay — Shares of the online marketplace jumped nearly 9% after GameStop made an unsolicited, non-binding offer Sunday to buy eBay for roughly $55.5 billion. GameStop CEO Ryan Cohe... Full story

Yahoo Finance • 25 days ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH]) * Tyson Foods (TSN [https://seekingalpha.com/symbol/TSN]) * Axsome Therapeutics (AXSM [ht... Full story

Yahoo Finance • 26 days ago

Why Axsome Therapeutics Stock Jumped Over 20% in April

Axsome Therapeutics(NASDAQ: AXSM) has been growing sales rapidly with its Auvelity antidepressant. The biopharmaceutical company focuses on developing therapies for central nervous system (CNS) disorders. Auvelity, launched in late 2022,... Full story

Yahoo Finance • 27 days ago

Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and confere... Full story

Yahoo Finance • 28 days ago

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease The safety and tolerability profile of AUVELITY in agitation associated with... Full story

Yahoo Finance • last month

Is Axsome Therapeutics (AXSM) Still Attractively Priced After Its 72% One-Year Surge

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. If you are wondering whether Axsome Therapeutics at around US$178... Full story

Yahoo Finance • 2 months ago

Axsome Faces Key Auvelity FDA Call And Insider Sentiment Test

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Axsome Therapeutics (NasdaqGM:AXSM) is awaiting an FDA decision this month on Auvelity for agitation associated with Alzhei... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says

Axsome Therapeutics (AXSM) could see meaningful upside ahead of a US Food and Drug Administration de PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

Axsome Therapeutics, Inc. Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS portfolio with a novel mecha... Full story

Yahoo Finance • 2 months ago

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics(NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter. What happened According to a Securities and Exchange Co... Full story

Yahoo Finance • 3 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether certain officers and directors of Atkore Inc. (NYSE: ATKR), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Capricor Therapeutics, Inc. (NASDAQ: CAPR),... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory

We came across a bullish thesis on Axsome Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on AXSM. Axsome Therapeutics, Inc.'s share was trading at $163.19 as of February 26th. AXSM’s forward... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary

Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Drivers Achieved 66% annual revenue growth driven by Auvelity's rapid uptake, which surpassed $500,000,000 in net sales in its third ful... Full story

Yahoo Finance • 3 months ago

Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036

Key Points Axsome Therapeutics' lineup and late-stage pipeline could help drive strong sales growth for a while. The biotech won't run into patent cliffs in the near future, either. 10 stocks we like better than Axsome Therapeutics › Axs... Full story

Yahoo Finance • 3 months ago

Boeing Holds In Buy Zone, Leads 5 Stocks To Watch In Short Trading Week

Five stocks with strong technical action from a variety of groups, include Boeing, Viking Holdings, TJX and an AI construction play. Continue Reading... Full story